Financing - May 20, 2020
Oncoinvent secures 40 million NOK
Oncoinvent has completed a 40 million NOK round of financing, led by Hadean Ventures and with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company pursue clinical development of its lead […]
Drug development - December 14, 2017
Oncoinvent opens new facilities
Yesterday, Oncoinvent held an opening ceremony for its new production and lab facilities. The new production facility contains a Grade B clean room, two Category B type isotope production suites, a quality control laboratory, and packaging area that will support qualified operations for manufacturing, analytical control, packaging and labelling of Radspherin for upcoming preclinical and […]
Collaboration - May 17, 2017
Oncoinvent announces positive results
The results of a collaboration between Oncoinvent and Sciencons researchers have been published in the Journal of Nuclear Medicine and Biology. The collaborators aim to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials. Alpha-particles have the potential to kill tumor […]
Financing - February 9, 2017
Oncoinvent closes $25 million private placement
Norwegian company Oncoinvent has announced the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Large privately owned investment companies joining the company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene Sundt AS and Must Invest AS. Oncoinvent AS is developing therapeutics to combat various […]
